Last update 26 Dec 2024
Recombinant Human nsIL12 Oncolytic Adenovirus(VacV Biotheraputics)
Last update 26 Dec 2024
Overview
Basic Info
Drug Type Oncolytic virus |
Synonyms Ad-TD-nsIL12, BioTTT001 |
Target |
Mechanism IL-12R stimulants(Interleukin-12 receptor stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization  VacV Biotheraputics (UK) LtdStartup |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
5
Clinical Trials associated with Recombinant Human nsIL12 Oncolytic Adenovirus(VacV Biotheraputics)评价重组人nsIL12溶瘤腺病毒注射液（BioTTT001）治疗复发/进展性高级别脑胶质瘤患者的安全性、耐受性、生物分布特征及初步疗效的Ⅰb/Ⅱ期临床研究
[Translation] A Phase Ib/II clinical study to evaluate the safety, tolerability, biodistribution characteristics and preliminary efficacy of recombinant human nsIL12 oncolytic adenovirus injection (BioTTT001) in the treatment of patients with recurrent/progressive high-grade brain glioma
A Clinical Study to Evaluate the Safety and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) in Combination With Toripalimab and Regorafenib in Patients With Liver Metastases From Colorectal Cancer
A Clinical Study to Evaluate the Safety and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) in Combination With SOX and Toripalimab in Patients With Peritoneal Metastases From Gastric Cancer
100 Clinical Results associated with Recombinant Human nsIL12 Oncolytic Adenovirus(VacV Biotheraputics)
Login to view more data
100 Translational Medicine associated with Recombinant Human nsIL12 Oncolytic Adenovirus(VacV Biotheraputics)
Login to view more data
100 Patents (Medical) associated with Recombinant Human nsIL12 Oncolytic Adenovirus(VacV Biotheraputics)
Login to view more data
100 Deals associated with Recombinant Human nsIL12 Oncolytic Adenovirus(VacV Biotheraputics)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| High grade glioma | Phase 2 | CN | 26 Nov 2024 | |
| Metastatic Gastric Carcinoma | Phase 2 | - | 02 Apr 2024 | |
| Secondary malignant neoplasm of peritoneum | Phase 2 | - | 02 Apr 2024 | |
| Colorectal Liver Metastases | Phase 1 | - | 02 Apr 2024 | |
| Metastatic Colorectal Carcinoma | Phase 1 | - | 02 Apr 2024 | |
| Advanced Malignant Solid Neoplasm | Phase 1 | CN | 28 Nov 2023 | |
| Head and Neck Neoplasms | Preclinical | CN | 30 Jan 2022 | |
| Melanoma | Preclinical | CN | 30 Jan 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free